A method is provided that includes intranasally dispensing nasal wash fluid (26) into a nasal cavity (22) of a subject such that the nasal wash fluid (26) washes biological material into an oropharynx (30) of the subject from (a) the nasal cavity (22), (b) a nasopharynx (32) of the subject, or (c) the nasal cavity (22) and the nasopharynx (32). Thereafter, a specimen sample (24) is collected that passed out of an anterior opening (34) of an oral cavity (36) of the subject and contains at least a portion of the biological material washed into the oropharynx (30) by the nasal wash fluid (26). Other embodiments are also described.

A steam room for sanitizing people's external body parts and clothes, but also their breathing airways and respiratory tract, to reduce viral load and thereby mitigate the likelihood of spreading or contracting Viral contamination. Steam room has precise temperature and relative humidity control of a heater and mist generator, in which the mist water molecules contain an accurate concentration of a Chlorine or Ethanol based disinfectant, so that the water vapor or combined air/water mixture in the room that comes in contact with the sanitized person reaches but does not surpass the globally permitted concentration of free Chlorine for swimming pools, dressing rooms and spas. The room has thermally isolated quick doors allowing rapid entry and exit, and the signaling to guide the person when to enter, stay and breath, and exit, in the most suitable timing profile for the application.

A system for applying a lavage fluid to a surface, the system having a body configured to house a lavage fluid and at least two interchangeable application members configured to be in fluid communication with the body, wherein the at least two interchangeable application members includes a first application member and a second application member, the first application member being configured to dispense the lavage fluid with a first fluid flow force and/or first fluid flow pattern, and the second application member being configured to dispense the lavage fluid with a second fluid flow force and/or second fluid flow pattern that is different from the first fluid flow force and/or fluid flow pattern, respectively.

A system for applying a lavage fluid to a surface, the system having a body configured to house a lavage fluid and at least two interchangeable application members configured to be in fluid communication with the body, wherein the at least two interchangeable application members includes a first application member and a second application member, the first application member being configured to dispense the lavage fluid with a first fluid flow force and/or first fluid flow pattern, and the second application member being configured to dispense the lavage fluid with a second fluid flow force and/or second fluid flow pattern that is different from the first fluid flow force and/or fluid flow pattern, respectively.

Some embodiments provided herein relate to methods, systems and kits for providing consistent intracoronary administration of a biologic to subjects having diverse coronary anatomies. In some embodiments, the biologic is an adeno-associated virus serotype 1 (AAV1) vector encoding sarcoplasmic/endoplasmic reticulum ATPase 2a (SERCA2a) protein.

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.

Provided is a COVID-19 respiratory therapy device, including: a main body (10) defining a predetermined interior space; a container (111) provided on an upper portion of the main body (10); an inhalation nozzle (50) installed on an upper portion of the container (111); a water tank (13) installed in the container (111) and having an open top; a vapor space defined by the container (111) and the inhalation nozzle (50); a vaporizer (20) installed in the water tank (13) and evaporating water in the water tank (13); a controller (30) provided in the interior space and controlling the vaporizer (20); and a discharge hole (53) provided on an upper portion of the inhalation nozzle (50).

An improved system and methods for treatment of cancer and other diseases including complications from late-stage viral infections by inducing hyperthermia in a patient relying on withdrawing blood from the patient and returning the withdrawn blood to the patient to establish an extracorporeal flow circuit. Blood is heated by passing through the extracorporeal circuit at a controlled rate until a target body core temperature in is achieved. Usually, the blood will be subjected to a continuously re-circulating dialysis to balance electrolytes. Additionally, the blood will be subjected to a continuously recirculating regeneration through a carbon sorbent column where toxins and contaminants are removed. The blood temperature is maintained at the target blood temperature for a treatment period, and the blood is cooled after the treatment period has been completed. The method can also be effective in treating rheumatoid arthritis, scleroderma, hepatitis, sepsis, the Epstein-Barr virus, and patients with life threatening complications from other viruses, including the COVID-19 virus. A method for removing viruses from the blood supply in an external circuit is also presented. An adjunct of the present invention is enhanced production of stem cells as a result of employing the HEATT process. A further adjunct is production of transgenic swine with extant viral infections.

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Antiviral biomimetic polymers (ABPs) are disclosed that can be used to prevent and/or treat viral disease. The ABPs are discovered by a process involving high-throughput screening of polymer libraries using disease-relevant bioactive molecules as target molecules. ABPs can be nanoscale (termed nanoABPs) or larger. Methods are described for the preparation and use of ABPs as prophylactics and therapeutics (in vivo) and as preventative agents, for example, in personal protective equipment (ex vivo). ABPs can be used to prevent and treat viral diseases including those caused by Filoviridae.